Item 8.01. Other Events.
On January 30, 2018, AveXis, Inc. (the Registrant) issued a press release to announce that the Registrant will initiate screening for the remaining patients in the Registrants pivotal trial of AVXS-101 for spinal muscular atrophy Type 1 as per the trial protocol, following review of safety data and early signals of efficacy from the first three patients dosed in the trial and with agreement from the U.S. Food and Drug Administration. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.